Critical appraisal of how COVID-19 infection and imposed lockdowns have impacted gastroesophageal reflux: A review.
Hafez AlmomaniIman AolymatSameer Al Haj MahmoudPublished in: Medicine (2024)
Previous literature has demonstrated that COronaVIrus Disease of 2019 (COVID-19) impacts an individual gastrointestinal tract (GIT), causing symptoms like nausea, diarrhea, and loss of appetite. Severe acute respiratory syndrome coronavirus RNA has been discovered in the stool of infected individuals in earlier research. It was discovered that severe acute respiratory syndrome coronavirus was significantly expressed in the GIT, indicating that the virus can also infect the digestive system. Angiotensin-converting enzyme 2 functions as the viral receptor. The chronic illness known as gastroesophageal reflux disease (GERD) is typified by frequent reflux of stomach acid into the esophagus. By triggering the sensitized esophageal-bronchial neuronal circuit or aspirating into the airways (microaspiration), GER exacerbates respiratory diseases. Aspiration is a well-known risk to be considered when treating patients in intensive care units. Strong genetic correlations have been identified between COVID-19 infection and GERD susceptibility, suggesting a shared genetic basis for both conditions. Nonetheless, even though GERD, extraesophageal reflex, and COVID-19 have a number of significant risk factors and exhibit similar symptoms, the relationship between these illnesses has not yet been examined in depth. This review is the first of its kind to critically examine the association between the COVID-19 epidemic and GER and its associated diseases. The key objective of this work is to promote the creation of prevention plans, treatment plans, and guidelines while also enhancing and optimizing our understanding of the relationship between COVID-19 and GERs.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- gastroesophageal reflux disease
- angiotensin converting enzyme
- risk factors
- intensive care unit
- cystic fibrosis
- end stage renal disease
- copy number
- angiotensin ii
- newly diagnosed
- ejection fraction
- health insurance
- weight loss
- prognostic factors
- genome wide
- clinical practice
- depressive symptoms
- combination therapy
- mechanical ventilation
- patient reported outcomes
- irritable bowel syndrome
- body weight